StockData
Monte Rosa Therapeutics, Inc. logo

Monte Rosa Therapeutics, Inc. (GLUE) company profile

GLUENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/3039% above fair value
$9.07−0.09 (-0.98%)

Close on Nov 17, 2026Market cap $773.79MP/E –Yield –

About Monte Rosa Therapeutics

Biological Products, (No Diagnostic Substances), SIC 2836

Monte Rosa Therapeutics is a clinical-stage biotechnology company that develops molecular glue degraders to selectively eliminate disease-associated proteins using cellular degradation mechanisms. The company designs small molecule therapies across immunology, inflammation, cardiology, and oncology through its proprietary QuEEN discovery platform. Its clinical-stage pipeline includes MRT-6160 for immune-mediated diseases, MRT-8102 for inflammasome-driven inflammatory conditions, and MRT-2359 for metastatic castration-resistant prostate cancer. Because the company currently has no commercial product sales, its primary counterparties are pharmaceutical collaborators, such as Novartis and Roche, which license and develop its drug candidates.

The company maintains research and development operations centered around an internal chemical library that includes more than 1,000 unique scaffolds and over 75,000 distinct molecular glue compounds. Its operational reach and business partnerships include activities in the United States and Switzerland. Monte Rosa Therapeutics is headquartered at its principal executive offices in Boston, Massachusetts.

Summary of the business section of Monte Rosa Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Monte Rosa Therapeutics, Inc.
Headquarters
Boston, MA
Address
321 Harrison Avenue, Suite 900 02118
Phone
(617) 949-2643
Employees
150, Dec 31, 2025
Industry
Biological Products, (No Diagnostic Substances)
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, Boston, Massachusetts

Stock & identifiers

Ticker
GLUE
Exchange
Nasdaq
IPO date
Jun 25, 2021
Shares outstanding
85M, Jul 31, 2026
Public float
$212.00M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1826457
CUSIP
61225M102
ISIN
US61225M1027
FIGI
BBG00X2VGZQ3
Share class FIGI
BBG00X2VGZR2
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Markus WarmuthPresident & CEO, Director585,038
Matthew BowenPrincipal Accounting Officer25,891
Jennifer ChampouxChief Operating Officer66,722
Sharon TownsonChief Scientific Officer68,245
Filip JankuChief Medical Officer60,612
Philip NicksonChief Business & Legal Officer55,000
Edmund DunnPrincipal Accounting Officer22,554
Ali BehbahaniDirector6,707,298
Anthony M. ManningDirector0
Christine SiuDirector–
Kimberly BlackwellDirector–
Jan SkvarkaDirector–
Andrew N. SchiffDirector–
Eric A. HughesDirector–
Chandra P. LeoDirector10,000

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Markus Warmuth
Chief Executive Officer
$650.00K$910.08K$3.04M$429.00K–$5.03M+106%
Filip Janku
Chief Medical Officer
$520.00K$255.96K$852.22K$299.60K$14.00K$1.94M+54%
Phil Nickson
Chief Business and Legal Officer
$520.00K$255.96K$852.22K$299.60K$14.00K$1.94M+51%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 25, 2021
Offer price
$19.00
Securities offered
11,700,000
Gross proceeds
$222.30M
Exchange
Nasdaq
First trading day
Jun 24, 2021
First-day close
$21.18+11.5%
Lock-up ends (est.)
Dec 21, 2021

“The initial public offering price is $19.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 150 full-time employees, of which 71 have M.D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?